Special considerations with the use of intravenous immunoglobulin in older persons

Drugs and Aging

Volumn 28, Issue 9, 2011, Pages 729-736

  Cheng, M Jennifer ^a   Christmas, Colleen ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Elderly; Immune globulin

Indexed keywords

CORTICOSTEROID; DIPHENHYDRAMINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ACUTE KIDNEY FAILURE; AGED; ARTERY THROMBOSIS; ARTICLE; DELIRIUM; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; MIGRAINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; TENSION HEADACHE; UNSPECIFIED SIDE EFFECT; URTICARIA; VEIN THROMBOSIS;

ACUTE KIDNEY INJURY; AGED; ARTERIES; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; VENOUS THROMBOSIS;

EID: 80052828850     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11592740-000000000-00000     Document Type: Article

References (37)

1. Iagaru N, Cinteza E, Cochino AV. Adverse reactions to intravenous immunoglobulin therapy [letter]. Maed J Clin Med 2007; 2 (4): 294
2. Leong H, Stachnik J, Bonk ME, et al. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008 Oct 1; 65 (19): 1815-24
3. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 Apr; 117 (4 Suppl.): S525-53
4. I.V. immunoglobulin therapy for infectious diseases. Drug Ther Bull 2010 May. 48;5:57-60
5. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008 Sep; 15 (9): 893-908
6. Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg): beyond immunodeficiencies and neurology. Clin Exp Immunol 2009 Dec; 158 Suppl. 1: 23-33
7. Vaitla PM, McDermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 2010 Jun; 49 (6): 1040-8
8. Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005 Dec; 29 (3): 173-84 (Pubitemid 43041668)
9. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005 Aug 15; 62 (16 Suppl. 3): S5-11
10. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007 Jan; 2 (1): 9-18 (Pubitemid 46723165)
11. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006 Apr; 6 (4): 535-42
12. Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010 Nov; 9 (6): 971-9
13. Gürcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007;Oct. 41;10:1604-10
14. Brannagan 3rd TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996 Sep; 47 (3): 674-7 (Pubitemid 26307296)
15. Dieppe P, Bartlett C, Davey P, et al. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004; 329: 31-4 (Pubitemid 38869999)
16. Stangel M, Hartung HP, Marx P, et al. Side effects of highdose intravenous immunoglobulins. Clin Neuropharmacol 1997 Oct; 20 (5): 385-93 (Pubitemid 27424328)
17. Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin- associated arterial and venous thrombosis; report of a series and review of the literature. Br JDermatol 2006 Oct; 155 (4): 714-21 (Pubitemid 44352551)
18. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006 Apr; 6 (4): 592-9
19. Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy: United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999 Jun 25; 48 (24): 518-21
20. Gras V, Andréjak M, Decocq G. Acute renal failure associated with intravenous immunoglobulins. Pharmacoepidemiol Drug Saf 1999; 8 Suppl. 1: S73-8 (Pubitemid 29201778)
21. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 2004 Dec; 34 (3): 593-601 (Pubitemid 39643121)
22. Shah SMA, Graeber CW. Acute renal failure following intravenous immunoglobulin therapy. Hospital Physician 2005 Mar; 41 (3): 29-32 (Pubitemid 40548569)
23. Epstein JS, Zoon KC. Dear Doctor Letter important drug warning: potential risk of acute renal failure reported to be associated with administration of immune globulin intravenous (human). Rockville (MD): US Food and Drug Administration, 1999 Sep 24 [online]. Available from URL: http://www.fda.gov/ BiologicsBloodVaccines/Safety Availability/ucm105901.htm. [Accessed 2011 Jun 17]
24. Golding B. Dear Manufacturer: immune globulin intravenous (human) (IGIV); required updates to product labeling. Rockville (MD): US Food and Drug Administration, 2003 Oct 16 [online]. Available from URL: http:// www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ ucm093491.htm [Accessed 2011 Jun 17]
25. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005 Jul; 16 (5): 313-8 (Pubitemid 41008736)
26. Caress JB, Hobson-Webb L, Passmore LV, et al. Casecontrol study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009 Mar; 256 (3): 339-42
27. Gelfand EW. Clinical uses of intravenous immunoglobulin continue to expand. Medscape Allergy and Clinical Immunology 2004 Apr 30 [online]. Available from URL: http://www.medscape.org/viewarticle/474408 [Accessed 2011 Jun 17]
28. Vo AA, Cam V, ToyodaM, et al. Safety and Adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006; 1: 844-52
29. Bollée G, Anglicheau D, Loupy A, et al. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 2008 Sep; 3 (5): 1461-8
30. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008 Mar; 51 (3): 491-503 (Pubitemid 351273478)
31. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006 Apr; 6 (4): 523-7
32. Feldmeyer L, Benden C, Haile SR, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol 2010 Sep; 90 (5): 494-7
33. Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008 Jun; 7 (6): 440-4
34. Katz U, Kishner I, Magalashvili D, et al. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006 Sep; 39 (6): 513-7 (Pubitemid 44575084)
35. Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008 Jan; 10 (1): 55-7 (Pubitemid 351649467)
36. Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011 Jan; 10 (3): 144-9
37. Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010 Jun; 9 (8): 553-9